Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Molecular Carcinogenesis
|
April 7, 2020
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
Michal J Besser, Orit Itzhaki, Guy Ben-Betzalel, et al.
Blood
|
November 8, 2003
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients
Gal Markel, Huda Mussaffi, Khoon-Lin Ling, et al.
European Journal of Immunology
|
July 20, 2004
Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients
Gal Markel, Hagit Achdout, Gil Katz, et al.
Cell Reports
|
June 7, 2016
CEACAM1-Mediated Inhibition of Virus Production
Alon Vitenshtein, Yiska Weisblum, Sebastian Hauka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
The Journal of Clinical Investigation
|
June 4, 2013
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth
Yael Nemlich, Eyal Greenberg, Rona Ortenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
Michal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
Immunity
|
February 15, 2015
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack
Chamutal Gur, Yara Ibrahim, Batya Isaacson, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
April 4, 2009
Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
Molecular Carcinogenesis
|
April 7, 2020
Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response
Michal J Besser, Orit Itzhaki, Guy Ben-Betzalel, et al.
Blood
|
November 8, 2003
The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients
Gal Markel, Huda Mussaffi, Khoon-Lin Ling, et al.
European Journal of Immunology
|
July 20, 2004
Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients
Gal Markel, Hagit Achdout, Gil Katz, et al.
Cell Reports
|
June 7, 2016
CEACAM1-Mediated Inhibition of Virus Production
Alon Vitenshtein, Yiska Weisblum, Sebastian Hauka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2010
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
Michal J Besser, Ronnie Shapira-Frommer, Avraham J Treves, et al.
The Journal of Clinical Investigation
|
June 4, 2013
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth
Yael Nemlich, Eyal Greenberg, Rona Ortenberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
Michal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
Immunity
|
February 15, 2015
Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack
Chamutal Gur, Yara Ibrahim, Batya Isaacson, et al.
The Lancet. Oncology
|
February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study
Reinhard Dummer, Jun Guo, Jason J Luke, et al.
Page
of 14